US 11596696
Combination therapy with an anti-CD25 antibody-drug conjugate
granted A61KA61K2039/505A61K31/5517
Quick answer
US patent 11596696 (Combination therapy with an anti-CD25 antibody-drug conjugate) held by ADC THERAPEUTICS SA expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ADC THERAPEUTICS SA
- Grant date
- Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K2039/505, A61K31/5517, A61K31/7068, A61K31/7076